Q1 EPS Estimate for ARS Pharmaceuticals Lowered by Analyst

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of ARS Pharmaceuticals in a research report issued to clients and investors on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($0.35) per share for the quarter, down from their previous estimate of ($0.25). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. William Blair also issued estimates for ARS Pharmaceuticals’ Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.39) EPS and FY2026 earnings at ($0.14) EPS.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings data on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.56. The firm had revenue of $86.58 million for the quarter, compared to the consensus estimate of $15.46 million.

A number of other analysts have also weighed in on the company. Leerink Partners raised their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Raymond James boosted their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 14th. Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They set an “outperform” rating and a $40.00 price target for the company. Finally, Scotiabank started coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $31.00.

ARS Pharmaceuticals Price Performance

SPRY stock opened at $12.36 on Monday. The business has a fifty day moving average price of $12.06 and a 200 day moving average price of $13.05. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -24.24 and a beta of 1.03.

Institutional Trading of ARS Pharmaceuticals

Large investors have recently bought and sold shares of the business. Barclays PLC boosted its holdings in shares of ARS Pharmaceuticals by 189.7% in the third quarter. Barclays PLC now owns 111,666 shares of the company’s stock valued at $1,618,000 after buying an additional 73,127 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in ARS Pharmaceuticals by 93.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 344,171 shares of the company’s stock worth $3,631,000 after purchasing an additional 165,950 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in ARS Pharmaceuticals by 766.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company’s stock worth $3,401,000 after purchasing an additional 207,456 shares in the last quarter. Peregrine Capital Management LLC acquired a new stake in shares of ARS Pharmaceuticals in the 4th quarter valued at about $4,469,000. Finally, State Street Corp lifted its holdings in shares of ARS Pharmaceuticals by 10.4% in the third quarter. State Street Corp now owns 2,049,542 shares of the company’s stock valued at $29,718,000 after purchasing an additional 193,321 shares in the last quarter. 68.16% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Eric Karas sold 10,000 shares of the company’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the sale, the insider now owns 7,696 shares in the company, valued at $107,744. This represents a 56.51 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Laura Shawver sold 49,600 shares of ARS Pharmaceuticals stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $11.21, for a total value of $556,016.00. Following the transaction, the director now owns 210,346 shares in the company, valued at approximately $2,357,978.66. This represents a 19.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 159,600 shares of company stock valued at $1,866,516 in the last ninety days. 40.10% of the stock is owned by insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.